A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH (ZENITH-2)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
Study Contact Backup
- Name: EU GSK Clinical Trials Call Center
- Phone Number: +44 (0) 20 89904466
- Email: GSKClinicalSupportHD@gsk.com
Study Locations
-
-
Queensland
-
Woolloongabba, Queensland, Australia, 4102
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- James Thomas
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Paris, France, 75651
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Vlad RATZIU
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Leipzig, Germany, 04103
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Ingolf Schiefke
-
-
-
-
-
Pokfulam, Hong Kong
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Loey Lung Yi Mak
-
-
-
-
-
Gunma, Japan, 370-0829
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Atsushi Naganuma
-
Kagoshima, Japan, 890-8520
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Seiichi Mawatari
-
-
-
-
-
Wellington, New Zealand, 6021
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Stephen Inns
-
-
-
-
-
Riyadh, Saudi Arabia, 11472
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Khalid Alswat
-
-
-
-
California
-
Arcadia, California, United States, 91006
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Elias Tarakji
-
Covina, California, United States, 91723
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Masoud Azizad
-
Los Angeles, California, United States, 90057
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Joseph Lamb
-
San Diego, California, United States, 92120
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Julie Doan Trang Vu
-
Santa Maria, California, United States, 93458
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Keval Shah
-
Van Nuys, California, United States, 91405
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Robert Jenders
-
-
Florida
-
Boynton Beach, Florida, United States, 33435-5610
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Aaron Cohen
-
Cape Coral, Florida, United States, 33914
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Paige Kreegel
-
Clermont, Florida, United States, 34711
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Edriss Estime
-
Doral, Florida, United States, 33016
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Jorge Diaz
-
Fort Myers, Florida, United States, 33912
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Charles Smith
-
Hialeah, Florida, United States, 33016
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Isaac Bassan
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Homestead, Florida, United States, 33033
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Gilberto Seco
-
Inverness, Florida, United States, 34452
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Paul Hellstern Jr.
-
Jacksonville, Florida, United States, 32216
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Jeffry Jacqmein
-
Kissimmee, Florida, United States, 34744
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Luis Alvarado Lopez
-
Lakeland, Florida, United States, 33803
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- James Andersen
-
Maitland, Florida, United States, 32751
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Eva Maria Heurich
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Miami, Florida, United States, 33144
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Carlos Ramos
-
Miami, Florida, United States, 33155
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Jorge Amaya
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Miami, Florida, United States, 33184
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Franciso Bautista
-
Miami, Florida, United States, 33135-4661
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Yaneicy Gonzalez Rojas
-
Miami, Florida, United States, 33156-7397
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Lazaro M Garcia
-
Miami, Florida, United States, 33173-3484
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Barbara Moscoso
-
Miami Lakes, Florida, United States, 33014
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Miguel Aponte
-
Ocala, Florida, United States, 34471
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Robert Barish
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Palmetto Bay, Florida, United States, 33157
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Karen Figueredo Reyes
-
Sarasota, Florida, United States, 34201
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Guy Neff
-
-
Kansas
-
Topeka, Kansas, United States, 66606
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Shekhar Challa
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
-
Louisiana
-
Marrero, Louisiana, United States, 70072
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Gary Reiss
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
-
Missouri
-
Springfield, Missouri, United States, 62703
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Dmitry Shuster
-
St Louis, Missouri, United States, 63141
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Fred Williams
-
St Louis, Missouri, United States, 63123
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Adrian Di Bisceglie
-
-
New Jersey
-
Jersey City, New Jersey, United States, 07059
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Samar Hameed
-
-
New York
-
East Syracuse, New York, United States, 13057
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Barbara Connor
-
New York, New York, United States, 10036-4103
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Eli Shalenberg
-
-
North Carolina
-
Morehead City, North Carolina, United States, 28557
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Kathryn Lucas
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
-
Ohio
-
Akron, Ohio, United States, 44320
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Ganesh Veerappan
-
Springboro, Ohio, United States, 45066
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Anjali Morey
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37421
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Chirag Patel
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
-
Texas
-
Austin, Texas, United States, 78759
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Michael Patrick Zimmerman
-
Austin, Texas, United States, 78745-5675
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Nomita Kim
-
Brownsville, Texas, United States, 78526
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Christopher Romero
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Dallas, Texas, United States, 75243
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Valentine Ebuh
-
DeSoto, Texas, United States, 75115
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Haresh Boghara
-
Richmond, Texas, United States, 77406
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Brian Chou
-
San Antonio, Texas, United States, 78229
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Emanuel DeNoia
-
San Antonio, Texas, United States, 78215
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Eric Lawitz
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
San Antonio, Texas, United States, 78209
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Robert Morin Jr
-
Seabrook, Texas, United States, 77586
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Joe Pouzar
-
Sugar Land, Texas, United States, 77479
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Harish Thakkar
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Tomball, Texas, United States, 77375
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Muhammad Irfan
-
Waco, Texas, United States, 76712
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Hanumantha Ancha
-
Waco, Texas, United States, 76710
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Gregg Lucksinger
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
-
Utah
-
West Jordan, Utah, United States, 84088
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Barbara Rizzardi
-
-
Virginia
-
Manassas, Virginia, United States, 20110
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Nabil Andrawis
-
-
Washington
-
Seattle, Washington, United States, 98105
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Kris Kowdley
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able and willing to understand and sign a written informed consent form (ICF) that must be obtained prior to the initiation of study procedures
- Age >=18 through <=75 years at enrolment
- History or presence of 2 or more of the 5 components of metabolic syndrome per American Heart Association definition
- History or presence of known or suspected MASH with evidence of fibrosis
Exclusion Criteria:
- ALT or AST >=5 × upper limit of normal (ULN)
- Total bilirubin (BILI) >=1.3 milligram per deciliter (mg/dL). Individuals with documented Gilbert's syndrome may be enrolled if they experienced an isolated increase in total BILI of >=1.3 mg/dL and direct BILI is <=20% of total BILI; otherwise, the individual will be excluded.
- Serum albumin <=3.5 grams per deciliter (g/dL)
- International normalized ratio (INR) >=1.3 not due to therapeutic anticoagulation. Individuals receiving chronic anticoagulant treatment with higher INR values may be enrolled at the discretion of the Investigator and Study Medical Monitor.
- Alkaline phosphatase (ALP) >=2 × ULN
- Platelet (PLT) count <140 000 per (/) cubic millimeter (mm^3); individuals with a PLT count between 110,000/mm^3 and 140,000/mm^3 may be enrolled after discussion with the Study Medical Monitor
- Serum creatinine >=1.5 mg/dL or creatinine clearance <=60 milliliter (mL)/minute (min)/1.73 square meter by Chronic Kidney Disease Epidemiology Collaboration equation.
- Alpha-fetoprotein >=20 nanogram per milliliter (ng/mL)
- HbA1c >=9.0%
- Model for End-Stage Liver Disease (MELD) 3.0 score >=12 unless the score is elevated in the absence of liver dysfunction (eg, Gilbert's syndrome)
- Phosphatidylethanol (PEth) >=80 nanogram per milliliter (ng/mL) at Screening
- Known co-infection with any of the following: a. Human immunodeficiency virus; b. Hepatitis B virus; c. Hepatitis C virus (HCV); d. Hepatitis D virus; or e. Hepatitis E virus.
- Chronic liver disease from any other cause including, but not limited to, alcoholic liver disease; evidence of portal hypertension; viral hepatitis, or any history or evidence of cirrhosis; or decompensated liver disease such as clinical ascites, bleeding gastroesophageal varices, hepatorenal syndrome, or hepatic encephalopathy prior to Screening or Day 1.
- Current or history of excessive alcohol intake for >=3 months within the 12-month period prior to Screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Efimosfermin Alfa Dose Level 1
Participants randomized to this group will receive Efimosfermin Alfa at dose level 1
|
Efimosfermin Alfa will be administered
|
|
Experimental: Efimosfermin Alfa Dose Level 2
Participants randomized to this group will receive Efimosfermin Alfa at dose level 2
|
Efimosfermin Alfa will be administered
|
|
Placebo Comparator: Placebo
Participants randomized to this group will receive Placebo
|
Placebo will be administered
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of participants with treatment-emergent adverse events (TEAEs) and TEAEs by severity
Time Frame: At Week 52
|
At Week 52
|
|
Number of participants with TEAEs leading to discontinuation and TEAEs leading to discontinuation by severity
Time Frame: At Week 52
|
At Week 52
|
|
Number of participants with Grade 3 and Grade 4 laboratory abnormalities
Time Frame: At Week 52
|
At Week 52
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Absolute Change from Baseline in enhanced liver fibrosis (ELF) score
Time Frame: Baseline (Day 1) and up to Week 52
|
The ELF score will be calculated using a published algorithm combining the values of a set of extracellular matrix markers.
The ELF score is used as a prognostic marker for disease progression: ELF score less than (<) 9.8: Low risk of progression, ELF score 9.8 to <11.3: Moderate risk of progression and ELF score greater than or equal to (>=) 11.3: High risk of progression.
|
Baseline (Day 1) and up to Week 52
|
|
Percent Change from Baseline in ELF score
Time Frame: Baseline (Day 1) and up to Week 52
|
The ELF score will be calculated using a published algorithm combining the values of a set of extracellular matrix markers.
The ELF score is used as a prognostic marker for disease progression: ELF score <9.8:
Low risk of progression, ELF score 9.8 to <11.3: Moderate risk of progression and ELF score >=11.3:
High risk of progression.
|
Baseline (Day 1) and up to Week 52
|
|
Number of participants achieving an improvement in ELF score greater than equal to 0.5
Time Frame: At Week 52
|
The ELF score will be calculated using a published algorithm combining the values of a set of extracellular matrix markers.
The ELF score is used as a prognostic marker for disease progression: ELF score <9.8:
Low risk of progression, ELF score 9.8 to <11.3: Moderate risk of progression and ELF score >=11.3:
High risk of progression.
|
At Week 52
|
|
Absolute Change from Baseline in vibration-controlled transient elastography (VCTE)- liver stiffness measurement (LSM) scores
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
|
Percent Change from Baseline in VCTE- LSM scores
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
|
Number of participants achieving a change from Baseline in VCTE-LSM >=30 percentage (%)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
|
Absolute Change from Baseline in magnetic resonance elastography (MRE) scores in the subset of participants
Time Frame: Baseline (Day 1) and up to Week 52
|
MRE is a non-invasive imaging technique that combine magnetic resonance imaging (MRI) scanning with low-frequency mechanical vibrations to measure the stiffness of liver.
MRE scores <2.5 is normal, 2.5 - 3.0 Normal or inflammation, 3.0 - 3.5 Stage 1-2 fibrosis, 3.5 - 4.0 Stage 2-3 fibrosis, 4.0 - 5.0 Stage 3-4 fibrosis and > 5.0 Stage 4 fibrosis.
|
Baseline (Day 1) and up to Week 52
|
|
Percent Change from Baseline in the subset of participants with magnetic resonance elastography (MRE) scores
Time Frame: Baseline (Day 1) and up to Week 52
|
MRE is a non-invasive imaging technique that combine MRI scanning with low-frequency mechanical vibrations to measure the stiffness of liver.
MRE scores <2.5 is normal, 2.5 - 3.0 Normal or inflammation, 3.0 - 3.5 Stage 1-2 fibrosis, 3.5 - 4.0 Stage 2-3 fibrosis, 4.0 - 5.0 Stage 3-4 fibrosis and > 5.0 Stage 4 fibrosis.
|
Baseline (Day 1) and up to Week 52
|
|
Absolute Change from Baseline in hepatic fat fraction (HFF) by magnetic resonance imaging (MRI)- derived proton density fat fraction (PDFF)
Time Frame: Baseline (Day 1) and up to Week 52
|
HFF is the percentage of fat in the liver measured by MRI proton density fat fraction technique, which ranges from 0-75%.
Greater than 5% is considered extra fat in the liver.
|
Baseline (Day 1) and up to Week 52
|
|
Percent Change from Baseline in HFF by MRI-PDFF
Time Frame: Baseline (Day 1) and up to Week 52
|
HFF is the percentage of fat in the liver measured by MRI proton density fat fraction technique, which ranges from 0-75%.
Greater than 5% is considered extra fat in the liver.
|
Baseline (Day 1) and up to Week 52
|
|
Absolute Change from Baseline in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (International units per liter)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
|
Absolute Change from Baseline in ALT and AST ratio (ALT/AST)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
|
Percent Change from Baseline in ALT and AST (International units per liter)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
|
Percent Change from Baseline in ALT and AST ratio (ALT/AST)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
|
Number of participants achieving ALT and HFF normalization
Time Frame: At Week 52
|
At Week 52
|
|
|
Number of participants achieving HFF less than equal to (<=) 5%
Time Frame: At Week 52
|
HFF is the percentage of fat in the liver measured by MRI proton density fat fraction technique, which ranges from 0-75%.
Less than or equal to 5% is considered normal (no significant fatty infiltration (steatosis) in the liver.
|
At Week 52
|
|
Change from Baseline in glycated hemoglobin (HbA1c) for participants with type 2 diabetes mellitus (T2DM)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
|
Change from Baseline in body weight for all participants(kilograms)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
|
Change from Baseline in fasting total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)- cholesterol, and fasting triglycerides (Millimoles per liter)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
|
Number of Participants with antidrug and anti-fibroblast growth factor 21 (FGF21) antibodies (ADA) at Week 52
Time Frame: At Week 52
|
At Week 52
|
|
|
Serum drug Concentration of efimosfermin alfa
Time Frame: Up to Week 52
|
Up to Week 52
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: GSK Clinical Trials, GlaxoSmithKline
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 306246
- 2025 (U.S. NIH Grant/Contract: Faculty of Social Sciences Scientific Grant at the University of Gdańsk)
- 2025-523674-16 (Other Identifier: EU CT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.